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1. Introduction
Uveal melanoma (UM) is the most common cause of primary eye cancer in the western
world. During embryogenesis neural crest cells migrate to the neural tract where they devel‐
op into melanocytes. Melanomas of the uvea are derived from these melanocytes. UM may
arise in the iris (5%), ciliary body (23%) or choroid (72%). Choroidal melanomas are the most
common and usually display a discoid, dome-shaped or mushroom shaped growth pattern.
Approximately 80% of the primary intraocular tumours are diagnosed as UM in patients
above the age of 20 years, with a mean age of 60 years (Singh & Topham, 2003). Despite a
shift towards more conservative eye treatments, survival has not improved during 1973 to
2008 (Singh et al, 2011). Growth of the primary tumour is related with histopathological fea‐
tures, as well as the genetic changes within these tumours. In this chapter we will not dis‐
cuss iris melanoma, as this shows a different clinical and genetic behaviour, compared to
ciliary body and choroidal melanoma. The clinical features, histopathological profile and ge‐
netic alterations of UM, as well as therapeutic options for primary tumours and metastases
will be discussed.
2. Epidemiology
The incidence of UM ranges from 4.3 to 10.9 per million (Singh et al, 2009). For the past fifty
years, the incidence has remained stable, unlike trends indicating a higher incidence of cuta‐
neous melanoma. The incidence in Europe and United States is comparable to that in Aus‐
tralia and New Zealand. In Europe, a lower incidence is reported in Spain and the south of
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Italy, about 2 per million, whereas registries in France, the Netherlands, Switzerland and
Germany has intermediate values around 4 to 5 per million. The United Kingdom registered
over 6 per million, and the highest incidence is up to > 8 per million in Norway and Den‐
mark (Virgili et al, 2007).
3. Predisposing factors
Men and women with UM are more or less affected equally (Damato & Coupland, 2012;
Singh et al, 2011). Iris melanoma is more common in women than in men (Damato & Coup‐
land, 2012). Several phenotypes, like blue or grey eyes and fair skin have been suggested to
predispose for UM (Schmidt-Pokrzywniak et al, 2009). This might explain why Caucasians
are approximately 150 times more frequently affected than Africans (Margo et al, 1998;
Singh et al, 2005a). In Asians UM is less common (Biswas et al, 2002).
From all the parts of the uvea the iris is most exposed to ultraviolet light, because of filtering
effects of the lens and retinal pigment epithelium (RPE), the choroid receives less light
(Singh et al, 2004). Although several epidemiologic and case control studies have been per‐
formed to investigate the influence of sunlight exposure on UM, the results are not conclu‐
sive (Guenel et al, 2001; Holly et al, 1990; Pane & Hirst, 2000; Shah et al, 2005; Vajdic et al,
2002). UM may occur as a part of familial syndromes, like xeroderma pigmentosa, Li-Frau‐
meni syndrome and familial breast and ovarian cancer. Of all UM 0.6% is considered to be
familial (Singh et al, 1996). In a retrospective study 0.0017% of the primary UM patients
were in the setting of familial atypical mole and melanoma syndrome (FAMM). These pa‐
tients were relatively young with a mean age of 40 years (Singh et al, 1995). Furthermore, an
association of neurofibromatosis type 1 and UM has been suggested, since both are of neural
crest origin, however this association remains unclear (Honavar et al, 2000). Ocular and ocu‐
lodermal melanocytosis (Nevus of Ota), dysplastic nevi and cutaneous melanoma are corre‐
lated with an increased risk of UM development (Carreno et al, 2012; Gonder et al, 1982;
Hammer et al, 1995; Richtig et al, 2004; Singh et al, 1998; Toth-Molnar et al, 2000; van Hees et
al, 1994). Additionally, in UM patients ocular and oculodermal melanocytosis are about 35
to 70 times more common (Carreno et al, 2012; Singh et al, 1998).
4. Clinical presentation
Depending on de location and size of the tumour, patients can present with visual com‐
plaints. Most UMs are detected during a routine ophthalmic examination. Approximately
30% of the patients have no symptoms at time of diagnosis, and if there are any complaints
these consist mostly of blurred vision, floaters, photopsias and visual field loss (Damato,
2010) (figure 1). Usually patients do not present with severe ocular pain, however, this can
occur secondary to inflammation or neovascular glaucoma.
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Figure 1. A large amelanotic uveal melanoma leads to a visual field defect.
5. Diagnosis
Diagnosis of UM is based on a combination of clinical examination with slit lamp biomicro‐
scopy, indirect ophthalmoscopy (figure 1, 2a, 3a) and ultrasonography (US) (figure 2b, 3b).
Iris melanomas are readily detectable by slit lamp biomicroscopy, whereas ciliary body tu‐
mours are hidden behind the iris and can be visualized by US. Choroidal tumours, depend‐
ing on their location, are diagnosed by dilated indirect ophthalmoscopy and US. In suspect
cases of intravenous fluorescein angiography can be helpful in differentiating melanomas
from other diagnoses. Also optical coherence tomography (OCT) and autofluorescence can
provide additional information (Lavinsky et al, 2007; Shields et al, 2008). In selected cases,
when in doubt, an intraocular biopsy is taken of the tumour.
Indirect ophthalmoscopy through a dilated pupil provides a correct diagnosis in more than
95% of the cases (Char et al, 1980). Accuracy of the right diagnosis is established to be over
99% by experienced clinicians with US, ophthalmoscopy, and fluorescein angiography and
confirmed by histopathology (Collaborative Ocular Melanoma Study Group, 1990). The abil‐
ity to differentiate melanoma from other lesions has improved over the last decades. When
comparing studies of 1964 and 1973, in 19% of the enucleated patients with the clinical diag‐
nosis melanoma no histopathological evidence of a melanoma was found (Ferry, 1964;
Shields, 1973). The accuracy in diagnosing medium to small sized tumours is quite challeng‐
ing. Nine percent of presumed melanomas are found to have another diagnosis by fine nee‐
dle aspiration biopsy (Char & Miller, 1995). Most important is to minimise the delay in
referring patients with melanoma to a specialised centre. It is reported that in 29% of the pa‐
tients a melanoma is missed during the first visit by an ophthalmologist, and that 31.5% of
the patients referred to an oncology centre with the diagnosis of melanoma actually had a
mimicking lesion (Eskelin & Kivelä, 2002; Khan & Damato, 2007).
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5.1. Characteristics
Melanoma are generally pigmented, but one fourth are relatively non-pigmented or amela‐
notic (figure 1). Melanoma can develop into two different directions: towards the vitreous
and outwards, through the underlying sclera. Having broken through Bruch’s membrane,
into the vitreous, UMs achieve a characteristic shape, even pathognomonic, like a ‘collar but‐
ton’ or ‘mushroom’. Small melanomas can appear flat or dome shaped.
5.2. Clinical prognostic factor
Well-known clinical prognostic factors are age and location of the tumour. Older patients
tend to have a worse prognosis (Shields et al, 2012). One study found that UMs were located
predominantly posterior and temporal or had a preference for macular zone, while others
found a more equal distribution of melanoma (Krohn et al, 2008; Li et al, 2000; Shields et al,
2009b). Patients with larger tumours, tumours that ruptured through Bruch membrane and
in patients who have developed metastasis, the tumours were significantly more often locat‐
ed anterior to the equator (Krohn et al, 2008).
Figure 2. a: A dark pigmented uveal melanoma with orange pigment; 2b: On B-scan ultrasonography acoustic hol‐
lowing and choroidal excavation is present, 2c: Subretinal fluid and retinal pigment epithelial alterations are visible on
optical coherence tomography scan at the top of the tumour.
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Figure 3. a: Pigmented uveal melanoma with orange pigment (lipofuscin); 3b: A homogeneous grey scale in the tu‐
mour and choroidal excavation on B-scan ultrasonography; 3c: Optical coherence tomography of the same tumour
with subretinal fluid.
The most important clinical prognostic factor is tumour size, and is often used for selection
of the treatment. There are several treatment options, which will be discussed later in this
chapter. UM are subdivided into different categories depending on the apical size and diam‐
eter, however, many centres use their own definition. Most widely used definition is sug‐
gested by the COMS study. Small melanomas are 1.0 - 2.5 mm in apical height and > 5.0 mm
in largest basal dimension (Collaborative Ocular Melanoma Study Group, 1997). Medium
tumours are defined as tumours 2.5 to 10 mm in apical height and ≤ 16 mm in largest basal
diameter. Large tumours are ≥ 2 mm in apical height and > 16 mm in maximal basal diame‐
ter, or a melanoma > 10 mm in apical height, regardless of the basal diameter (Collaborative
Ocular Melanoma Study Group, 2003). One large study described that each increase in milli‐
meter of tumour thickness increased the risk for metastasis by 5% (Shields et al, 2009b). The
mortality rate for small (< 2 - 3 mm height), medium (3 - 8 mm height) and large (> 8 mm
height) melanoma was 16%, 32% and 53% in 5 years, respectively, and has not changed in
recent years (Diener-West et al, 1992). This supports the model of tumour doubling time of
melanoma and its’ related metastasis. The model suggests that micrometastasis already exist
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several years before diagnosis of the primary tumour (Eskelin et al, 2000). This emphasizes
the importance of identifying small melanoma and reducing the risk of metastases.
5.3. Clinical predictive factors of small melanoma
In  general,  choroidal  nevi  have  a  less  than  5  mm  basal  diameter  and  are  minimal  in
height (< 2 mm), although several definitions of nevi have been proposed. Due to differ‐
ent  examination  methods  and  definitions,  the  prevalence  of  nevi  is  between  0.2%  and
30% (Gass,  1977;  Wilder,  1946).  Overall  in a Caucasian population the incidence is  6.5%
(Sumich et al,  1998). Whenever, growth of a nevus is measured on US in a short time a
transformation into a small  melanoma is  suspected.  On the other hand benign nevi  can
also grow slowly. Mashayekhi et al observed in 31% of nevi a slight growth, without evi‐
dence of development into a melanoma over a mean follow up of 15 years (Mashayekhi
et  al,  2011).  As  described by Singh and co-workers,  assuming that  all  melanoma result
from nevi, 1 out of 8845 choroidal nevi can undergo malignant transformation into mela‐
noma in the Caucasian population in the USA (Singh et al, 2005b). In Australia this is es‐
timated 1 out of 4300 nevi (Sumich et al, 1998).
It is important to differentiate melanoma form other choroidal pathologies, such as choroi‐
dal nevi, by identifying indicators of potential malignancy which may differentiate nevi
from small UM. Shields et al constructed a mnemonic “TFSOM”, i.e. “to find small ocular
melanoma” to assist in identifying small choroidal melanoma at risk for growth (Shields et
al, 1995). The letters of the mnemonic indicate: Thickness > 2 mm, subretinal Fluid, Symp‐
toms, Orange pigment and Margin to the optic disc. Tumours with no, one or more than two
factors have 4%, 36% or > 45% chance of growth, respectively (Shields et al, 2000). A tumour
with a thickness of more than 2 mm is considered suspect of being a melanoma rather than a
nevus. Subretinal fluid is the strongest indicator of malignancy. Exudative retinal detach‐
ment, overlying or adjacent to the tumour, is associated with tumour growth (Augsburger et
al, 1989). Presence of symptoms, as mentioned earlier or a change in symptoms is a risk fac‐
tor for malignancy. Orange pigment is formed on melanomas of the posterior pole, although
this can also be seen on the surface of presumed benign nevi and haemangioma. Orange
pigment is an accumulation of lipofuscin within the RPE. In amelanotic tumours it appears
brown-black of colour. Besides orange pigment as a risk factor, a tumour margin within 3
mm of the optic disc is also suspect for malignant potential (figure 4a).
Later  “Using  Helpful  Hints  Daily”  was  added  to  “TFSOM”  mnemonic  (Shields  et  al,
2009a). These features indicate a low acoustic profile or Ultrasound Hollowness, absence
of a Halo around the tumour and absence of Drusen over the tumour. US hollowness is
shown in 25% of nevi that transformed into melanoma, compared to the 4% with growth
without US hollowness (Shields et al, 2009a). A halo around a tumour is a pigmented le‐
sion with a surrounding depigmentation, as can also be noticed in dysplastic nevi.  Dru‐
sen suggest a chronic lesion and usually indicate that the tumour is benign, however this
is not conclusive.
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Figure 4. a: Peripapillary nevus, barely elevated, with margin located < 3 mm to the optic disc in the right eye of a 72
year-old man; 4b: High reflectivity on B-scan ultrasonography.
5.4. Ancillary testing
5.4.1. Ultrasonography
US is a non-invasive tool and helps to establish the diagnosis of UM, despite media opacities
or whether the tumour is located far peripherally. UM shows characteristic low to medium
internal reflectivity on A-scan. B-scan US is primarily used to plan therapy based on the first
measurement, and to periodically measure tumour prominence (height) and basal diameter
for follow-up. The B-scan can identify possible extraocular extension as an empty area be‐
hind the sclera. On B-scan US the internal structure of the tumour is typically seen as a rela‐
tive homogeneous grey scale, although this pattern is not specifically diagnostic (figure 3b).
At the base of the tumour an acoustically silent zone (called acoustic hollowing) is seen, as
well as choroidal excavation and shadowing in the orbit (figure 2b). Eighty-eight percent of
the UM show US hollowness or low acoustic reflectivity (Boldt et al, 2008). Choroidal exca‐
vation is not observed in all melanomas and varies from 42% to 70% (Coleman et al, 1974;
Sobottka et al, 1998; Verbeek, 1985). US provides accurate measurements with an interob‐
server variability of 0.5 mm (Char et al, 1990).
5.4.2. Fluorescein angiography
The diagnostic value of fluorescein angiography in UM is limited. Fluorescein angiography
does not show pathognomonic patterns and is especially helpful in differentiating lesions,
which simulate melanoma. The pigmentation, size and effect on the RPE of the tumour in‐
fluence the fluorescein angiogram. It is of little help in some medium to large melanomas
that have an intrinsic tumour circulation. This ‘double circulation’ (simultaneous visualiza‐
tion of retinal and choroidal circulation) consists of late staining of the lesion and multiple
pin-point leaks at the level of the RPE, which is evident in the early phase of the angiogram.
Blockage of background fluorescence and late staining, when fluorescein leaks from the ves‐
sels can be seen on an angiogram as well (Atmaca et al, 1999). Characteristic signs are hypo‐
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fluorescence in the early phase followed by diffuse hyperfluorescence and hyperfluorescent
spots (due to changes in RPE). In the late phase the dye accumulates in the tumour tissue
and hyperfluorescents (figure 5b). Hypofluorescent spots correspond with deposits of or‐
ange pigment on the surface of the tumour.
Figure 5. a: A partly pigmented and non-pigmented uveal melanoma; 5b: Fluorescein angiogram with blockage of
the background and fluorescein leaking from the vessels.
5.4.3. Indocyanine green angiography
Indocyanine green angiography is designed to visualize the choroidal vessels and provides
more information than fluorescein angiography. Whether an evident pattern can be seen on
an angiogram depends on the pigmentation, thickness, disruption through Bruch’s mem‐
brane and vascularisation of the tumour (Atmaca et al, 1999). More fluorescence is seen in
less pigmented and larger tumours. The choroidal vasculature can be better visualised with
indocyanine green than fluorescein. On indocyanine green late staining is observed, because
of the leaking of indocyanine green in the extracellular space of the tumour (Frenkel et al,
2008; Guyer et al, 1993; Stanga et al, 2003).
5.4.4. Optical coherence tomography and fundus autofluorescence
OCT and fundus autofluorescence imaging have limited use in detecting changes in the cho‐
roid, however, both techniques are non-invasive and of help in identifying subtle changes in
the RPE, retina and vitreoretinal interface. By means of an OCT subretinal fluid can be vi‐
sualized and quantified, small tumours can be measured, whereas with fundus autofluores‐
cence orange pigment can be shown. Spectral domain OCT can be useful in the detection of
subretinal deposits, vitreous seeding and transretinal tumour extension (Heindl et al, 2009).
Although OCT itself is not useful in diagnosing uveal melanoma, it aids in differentiating
other pigmented lesions from melanomas (Schaudig et al, 1998). For example, melanocyto‐
ma tend to have a high reflective signal anteriorly, corresponding with the nerve fibre layer,
and an optical shadowing posteriorly (Muscat et al, 2001). In most choroidal nevi no charac‐
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teristic or subtle patterns of autofluorescence were observed (Lavinsky et al, 2007; Shields et
al, 2008). Choroidal melanoma and related retinal and RPE changes, show different auto‐
fluorescence patterns, and secondary changes, such as subclinical retinal detachments asso‐
ciated with presence of small amounts of subretinal fluid can discriminate small choroidal
melanoma and nevi at risk for growth (Muscat et al, 2004). Like some nevi UM show bright‐
er hyperautofluorescence in overlying orange pigment, RPE detachment and subsequently
decreased brightness in subretinal fluid and drusen (Shields et al, 2008) (figures 2c and 3c).
5.4.5. Magnetic resonance imaging and computed tomography
Magnetic resonance imaging (MRI) and computed tomography (CT) can be of additional
value in the differential diagnosis of UM. On CT an UM appears as a hyperdense lesion
with moderate contrast enhancement. Tumours thinner than 2 mm are not detectable on
CT. Besides that, CT is less accurate than US in differentiating melanoma and is more ex‐
pensive (Mafee et al, 1986; Peyster et al, 1985). For extrascleral extension CT is inferior to
US (Scott  et  al,  1998).  On the other  hand,  MRI seems more sensitive  and more specific
than US for  detection of  extraocular  extension of  UM (Hosten et  al,  1997).  A choroidal
melanoma appears hyperintense on a T1 and hypointense on a T2 weighted scan. As this
can also be the appearance of a melanocytoma, MRI is not specific for uveal melanoma.
Due to  the higher  expenses of  CT and MRI and the superiority  of  US,  both techniques
are not routinely used for diagnostic evaluation.
5.5. Differential diagnosis
About 54 different conditions are able to simulate UM. The most frequent diagnosis is cho‐
roidal nevus, accounting for 49% of the approximately 1739 presumed melanoma patients
referred to a large tertiary Oncology Department in the USA (Shields et al, 2005b). The dif‐
ferentiation between small melanomas and choroidal nevi remains a clinical challenge. Clin‐
ical features that are more prevalent in choroidal nevi than in melanomas are drusen and RPE
changes, whereas retinal detachment, choroidal neovascularisation or haemorrhagic retinal
detachment can occur in both. On B-scan US, nevi have a high internal reflectivity (figure
4b). Also orange pigment and subretinal fluid, which are features of potential malignancy as
mentioned previously, can be present in nevi. Ten percent of the nevi have orange pigment
and 18% have subretinal fluid.
Congenital hypertrophy of the retinal pigment epithelium (CHRPE) has sharper edges than mela‐
noma and usually sharply bordered nonpigmented areas (lacunae), or a depigmentated or
pigmented halo within. The lesions might be slightly elevated and are black or grey of col‐
our. CHRPE is a benign lesion and is typically located in the peripheral fundus. On the other
hand, adenocarcinomas arising from a CHRPE have been reported (Shields et al, 2009e).
Optic disc melanocytoma is a heavily pigmented benign lesion with a fibrillated or feathery
margin. Although it can occur anywhere in the uveal tract, the tumour is most often located
unilateral and on or nearby the optic disc. Optic disc melanocytoma is a variant of melano‐
cytic nevus. Most patients (75%) have no visual complaints, whereas patients with visual
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loss were related to neuroretinitis from tumour necrosis and secondary subretinal fluid of
the fovea (Shields et al, 2006; Shields et al, 2004). In addition, visual field defects have been
described (Meyer et al, 1999; Shields et al, 2006). Ocular melanocytosis is associated with
melanocytoma in 8% of cases, and melanocytoma enlargement is noticed in 57% within 8
years (Lee et al, 2010) and 32% within 10 years (Shields et al, 2004). Although malignant
transformation is extremely rare, it has been reported (Meyer et al, 1999; Shields et al, 2004).
Hyperplasia of the RPE is a common ocular finding, which is idiopathic or develops in re‐
sponse to trauma, inflammation, haemorrhage and retinal detachment. It is characterised as
a black irregular usually small retinal lesion consisting of proliferated RPE cells. Intraretinal
pigmented spicules can be seen, and when it manifests as a subretinal localized mass, a mel‐
anoma can be suspected.
Choroidal haemangioma is a benign tumour consisting of blood vessels with a typical red to
orange colour. Some areas of increased pigmentation can be observed, which makes it diffi‐
cult to differentiate from melanoma. On angiography typical early hyperfluorescence is
shown and on US a characteristic high internal reflectivity is present.
Choroidal  metastases  are  the  most  common  intraocular  malignancies.  The  prevalence  of
uveal metastases from all forms of carcinoma is between 2% and 9%, with a mean of 7%
for  breast  cancer  and 5% for  lung cancer  (Kanthan et  al,  2007).  The origin of  choroidal
metastases  is  predominantly breast  cancer  in woman and lung cancer  in man.  Less  fre‐
quently  patients  are  diagnosed  with  other  primary  tumours,  such  as  gastrointestinal
tract, kidney, skin and prostate carcinoma (Shields et al, 1997). Choroidal metastases typi‐
cally develop after the diagnosis of breast cancer and in some cases systemic metastases
have already been detected. In 66% to 97% of lung cancer patients, choroidal metastases
are detected after the primary tumour has been diagnosed (Kanthan et al,  2007). In con‐
clusion, uveal metastases can also be observed before the diagnosis of breast or lung can‐
cer (Demirci et al, 2003; Singh et al, 2012). The median interval between diagnosis of the
primary tumour and uveal metastasis is 1 - 4.5 years (Amer et al, 2004; Ratanatharathorn
et al, 1991; Rosset et al, 1998; Rottinger et al, 1976; Tsina et al, 2005). Choroidal metasta‐
ses are creamy yellow, flat or elevated and often multilobulated lesions that can occur bi‐
lateral. More than half of the patients may develop subretinal fluid (Demirci et al, 2003).
The lesion can show clumps of brown pigmentation, known as leopard spots and RPE al‐
terations.  Metastases  grow in  a  different  fashion than primary UMs,  they  infiltrate  and
replace the normal choroidal  architecture more diffusely.  On US metastases from breast
carcinoma show a higher internal reflectivity than UM (Sobottka et al, 1998).
Choroidal osteoma is a rare ossifying benign lesion of the choroid that appears as a yellowish
to orange well-defined, juxtapapillary or macular choroidal tumour. These lesions mostly
occur in young women with a mean age of 26 years; usually it occurs unilateral, although in
20-30% of cases it appears to be bilateral. Over time an osteoma may enlarge and decalcify
partially or totally (Ross & Kemp, 2009; Shields et al, 2005a). There is a 31% chance of devel‐
oping choroidal neovascularisation after 10 years (Shields et al, 2005a). On B-scan US a high‐
ly reflective lesion that shadows the orbit can be seen.
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Peripheral exudative hemorrhagic chorioretinopathy (PEHC) lesions, unilateral and often bilater‐
al, have peripheral (> 3 mm outside the fovea) subretinal or sub-RPE haemorrhage that aris‐
es from choroidal neovascularisation. In the periphery signs of macular degeneration, such
as lipid exudation, subretinal fluid and fibrosis can be observed (Mantel et al, 2009; Shields
et al, 2009c). Also in the macula drusen, RPE alterations or choroidal neovascularisation can
be present, which is then consistent with macular degeneration (Shields et al, 2009c). On B-
scan internal lesion characteristics show a solid or hollow acoustic quality and no choroidal
excavation (Mantel et al, 2009; Shields et al, 2009d). The majority of the peripheral lesions
resolve spontaneously over time, leaving a scar.
Hemorrhagic detachment of the retina and RPE may also simulate melanoma.
Choroidal haemorrhage may be distinguished from UM by partially or totally resorption of the
haemorrhage over a few weeks, and on US an after-movement can be noticed by kinetic
evaluation. Key features are elevated eye pressure, forward movement of diaphragm com‐
bined with severe pain (Yang et al, 2003).
Posterior nodular scleritis is rare, but often underdiagnosed. It is twice as common in women
as in men, and in 35% of the patients it occurs in both eyes. The most common symptoms
are periocular pain, pain with eye movement and decreased vision. The differentiation be‐
tween scleritis and melanoma can be made by US. On B-scan echogenic scleral nodules, flu‐
id in Tenon’s capsule, swelling of the optic disc and serous retinal detachment are found
(McCluskey et al, 1999).
Intraocular leiomyoma is a rare benign amelanotic tumour of the uvea and mimics an UM. It
presents as a dome-shaped lesion, showing light translucency and often contains dilated
episcleral vessels, with a predilection in young females (Shields et al, 1994). Sometimes the
diagnosis cannot be made by non-invasive examination and intraocular biopsy is necessary
(Richter et al, 2003).
Adenoma of the RPE is infrequently diagnosed before enucleation. RPE adenoma is dome-
shaped and has in contrast to melanoma a higher internal reflectivity on A-scan US (Naka‐
mura et al, 2012). Compared to UM, RPE adenoma has more frequently retinal feeder
vessels, retinal or subretinal exudates and exudative retinal detachment (Wei et al, 2010).
6. Classification and histopathologic features
UMs develop from melanocytes of the uvea that are derived from neural crest cells. Initially
Callender and colleagues described several melanoma cell types, (Callender, 1931) currently
three histopathological uveal melanoma categories are being recognised: spindle, epithelioid
and mixed cell type (Campbell et al, 1998). Haematoxylin and eosin (H&E) staining is used
to differentiate between cell types. Spindle cells exhibit elongated nuclei that may contain
eosinophilic nucleoli. In general, Ums containing spindle cells grow slowly and might be as‐
sociated with better prognosis. On the other hand, UMs consisting of faster growing epithe‐
lioid cells, have a more aggressive behaviour, and are therefore associated with poor clinical
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outcome. Epithelioid cells have more polygonal cytoplasm and contain eccentric placed
large pleomorphic nuclei and prominent eosinophilic nucleoli (figure 6). The mixed-cell type
melanoma has variable proportion of spindle and epithelioid cells with a minimum of 10%
of any one type (Edge & American Joint Committee on Cancer, 2010). Other inter-tumour
factors, like the presence of certain extracellular matrix patterns (three closed loops located
back to back identified by Periodic-acid Schiff (PAS) staining) and increased mitotic figures
(number of mitoses per 50 high-power fields equal to 8mm2) can both provide additional
adverse prognostic information (Folberg et al, 1993; Mooy et al, 1995). Other histological fea‐
tures associated with mortality and metastases are mean diameter of ten largest nucleoli, de‐
gree of pigmentation, presence of inflammation and tumour necrosis (Gill & Char, 2012).
Extrascleral extension by perineural, perivascular, intravascular or direct scleral invasion is
correlated with a worse prognosis, especially when the orbital fat resection margin is posi‐
tive (Collaborative Ocular Melanoma Study Group, 1998).
Immunohistochemistry may be of diagnostic value. S-100 is expressed by cells of neuroecto‐
dermal origin. HMB-45 binds to gp100, an antigen expressed by melanocytes that can be
useful in differentiating UM from nonmelanocytic tumours (Burnier et al, 1991).
Figure 6. a: Haematoxylin and eosin staining of formalin fixed and paraffin embedded eye sample with a typical
mushroom shaped melanoma.; 6b: Uveal melanoma tissue with spindle cell type characterised by elongated nuclei;
6c: Uveal melanoma tissue with epithelioid cells containing large pleomorphic nuclei and prominent eosinophilic nu‐
cleoli.
7. Genetic classification
Cytogenetic studies in solid tumours have been a greater challenge than in haematological
malignancies since metaphase chromosome spreads of good quality are more difficult to ob‐
tain. Solid tumours frequently have highly complex chromosome alterations and are more
heterogeneous. Despite this, UM has been well studied since the late eighties with different
techniques, such as cytogenetic and fluorescent in situ hybridization (FISH) analysis. Over
the years, we have learned that the majority of UMs contain non-random chromosomal
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anomalies on either the short arm (p) and or long arm (q) of chromosomes 1, 3, 6 and 8,
which can serve as prognostic markers.
7.1. Cytogenetic and molecular techniques in UM research
To examine chromosomal changes in UM tissue several cytogenetic and molecular techni‐
ques are available. UMs are quite suitable for cytogenetic analysis because of their relatively
simply karyotype. Large chromosomal gains, deletions and translocations can be visualized
with conventional karyotyping and spectral karyotyping (SKY) (figure 7a). However, for the
detection of smaller abnormalities other techniques are necessary, such as FISH (figure 7b),
comparative genomic hybridization (CGH) or quantitative polymerase chain reaction
(qPCR) based techniques. An approach is the multiplex ligation probe amplification (MLPA)
which allows the relative quantification of multiple loci in one single reaction. MLPA can
detect patients at risk for metastatic disease using the results for chromosome 3 and 8 with
similar accuracy as FISH (Damato et al, 2009; Vaarwater et al, 2012). MLPA and other qPCR-
based techniques as Multiplex Amplicon Quantification (MAQ) fill the gap between more
expensive genome-wide screening assays and cheaper methods that only provide informa‐
tion on a single locus (Kumps et al, 2010). A different technique is microsatellite analysis
(MSA). Microsatellites are tandem repeats of polymorphic sequences located in the non-cod‐
ing regions of DNA. An extreme form of microsatellite instability was first described in he‐
reditary nonpolyposis colorectal cancer syndrome (Thibodeau et al, 1993). This technique is
used to study loss of heterozygosity (LOH) as an indicator of chromosomal loss. A draw‐
back of MSA is that only a limited number of markers can be analyzed in one experiment.
Figure 7. a: Example of a karyogram showing monosomy 3 and trisomy of chromosome 8; 7b: FISH analysis of a tu‐
mour demonstrates 1 signal for the probe on centromere 3 (green signals) and 3 to 4 signals of the probe on centro‐
mere 8 (red signals).
After completion of the human genome project, genome-wide DNA assays became availa‐
ble. Micro-assay based CGH, single nucleotide polymorphism (SNP) analysis and gene ex‐
pression profiling (GEP) analysis are the frequently applied techniques. With the
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development of Next Generation Sequencing (NGS) technologies, the genome can be ana‐
lyzed at base pair level. Genome-wide mutation analysis of tumour samples led to the dis‐
covery of a subset of genes in UM such as GNAQ and BAP1.
7.2. Chromosomal anomalies
7.2.1. Monosomy 3
Monosomy of chromosome 3 is observed in approximately 50% of the cases of UM and is
strongly associated with clinical and histopathological prognostic factors and with metastat‐
ic death (Horsman et al, 1990; Prescher et al, 1990; Sisley et al, 1990). Prescher and associates
were the first to find a strong correlation between loss of chromosome 3 and a poor progno‐
sis of the patient (Prescher et al, 1996). Since then several groups have confirmed the prog‐
nostic value of monosomy 3 (Kilic et al, 2006; Sisley et al, 2000; Sisley et al, 1997; White et al,
1998). It is assumed that loss of chromosome 3 is a primary event, as it often occurs with
other chromosomal aberrations in UM such as 1p loss, and gain of 6p and 8q (Prescher et al,
1995). Kiliç and colleagues established that tumours with concurrent loss of chromosome 1p
and 3 are at higher risk of metastasizing than the tumours with other aberrations (Kilic et al,
2005). Mostly one entire copy of chromosome 3 is lost, although in some cases, isodisomy of
chromosome 3 is acquired (Aalto et al, 2001; Scholes et al, 2001; White et al, 1998). Partial
deletions or translocations have rarely been described on this chromosome making it diffi‐
cult to map putative tumour suppressor genes. However, recently a mutation in the BAP1
gene, located on chromosome 3, has been identified in UMs and this gene seems to play an
important role in the tumour progression (Harbour et al, 2010). This gene will be discussed
in more detail later in this chapter.
7.2.2. Chromosome 8
Abnormalities in chromosome 8, and in particular gain of 8q or an isochromosome 8q, are
thought to be a secondary event in UM as variable copy numbers can be present in one mel‐
anoma (Horsman & White, 1993; Prescher et al, 1994). Gain of chromosome 8q is frequently
found in tumours that also have loss of chromosome 3, and this is associated with a poor
patient outcome (Aalto et al, 2001; Prescher et al, 1995; White et al, 1998). A SNP array analy‐
sis with this chromosome status is depicted in figure 8. The relationship between the percen‐
tages of aberrant copy numbers within UM cells and patient outcome has been investigated.
A higher percentage of monosomy 3 and chromosome 8q gain in primary UM cells shows a
strong relation with poor disease-free survival compared to low percentage aberrations (van
den Bosch et al, 2012).
7.2.3. Chromosome 6
Rearrangements on chromosome 6 affect both arms of the chromosome, resulting in dele‐
tions of 6q and gains of 6p. The relative gain of chromosome 6p can occur either through an
isochromosome of 6p or a deletion of 6q. Tumours with gain of 6p are thought to be a sepa‐
rate group within UM with an alternative genetic pathway in carcinogenesis, since gain of
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6p is frequently found in tumours with disomy 3 (Ehlers et al, 2008; Hoglund et al, 2004;
Sisley et al, 1997). However, this combination of gain of 6p with disomy 3 could not be con‐
firmed by others (Mensink et al, 2009). Aberrations resulting in a relative increase of 6p have
been found to be related with both a longer survival (White et al, 1998) or a decreased sur‐
vival (Aalto et al, 2001). The effect of chromosome 6 aberrations on patient outcome is not
conclusive.
Figure 8. Single nucleotide polymorphism (SNP) array of an uveal melanoma. The upper panel (LogR ratio) shows loss
of chromosome 3, partial loss of chromosome 8p and gain of chromosome 8q. The lower panel depicts the B-allele
frequency representing allelic imbalance at these chromosomes.
7.2.4. Chromosome 1
In cutaneous melanoma rearrangements on the short arm of chromosome 1 are a common
abnormality, occurring in about 80% of all cases (Fountain et al, 1990; Zhang et al, 1999). In
UM this region on 1p is also frequently affected, giving rise to a deletion of 1p. However,
these anomalies on chromosome 1 are less common than those in skin melanomas with a
frequency of approximately 30% (Horsman & White, 1993; Parrella et al, 1999; Prescher et al,
1990; Prescher et al, 1995; Sisley et al, 2000).
Aberrations on other chromosomes have been explored, such as chromosome 9p21 (Scholes
et al, 2001), chromosome 11q23 (Sisley et al, 2000), chromosome 18q22 (Mensink et al, 2008;
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White et al, 2006), and chromosome 16q (Kilic et al, 2006; Vajdic et al, 2003). The impact on
the prognosis, however, remains unclear due to contradictory findings.
7.2.5. Gene expression profiling
Using GEP UMs can be classified into two classes of tumours that correspond remarka‐
bly well with the ability of the tumour to metastasize. In a study of 25 UMs, class 1 tu‐
mours had a low risk of metastasizing and class 2 tumours had a high risk of developing
metastasis  (Onken et  al,  2004).  This  molecular  classification  strongly  predicts  metastatic
death and outperforms other clinical, histopathological and cytogenetic prognostic indica‐
tors (Petrausch et al, 2008; van Gils et al, 2008; Worley et al, 2007). Class 1 tumours pre‐
dominantly  show disomy of  chromosome 3,  whereas  class  2  tumours  consist  mostly  of
monosomy 3 (Worley et al, 2007).
7.3. Candidate genes
After identifying the non-random chromosomal alterations in UM, the search for potential
oncogenes and tumour suppressor genes followed. By narrowing down altered regions on
chromosomes, researchers have tried to identify genes involved in tumourigenesis or pro‐
gression towards metastasis. This way, studies have been conducted on chromosome 8q re‐
vealing potential oncogenes such as MYC, which is amplified in about 30% of the UMs
(Parrella et al, 2001). Other oncogenes on chromosome 8q have been described, such as
DDEF1 and NBS1 (now referred to as ASAP1 and NBN, respectively) (Ehlers & Harbour,
2005; Ehlers et al, 2005). Yet, no specific oncogenic mutations on this region have been re‐
ported thus far. Other candidate genes were proposed, such as HDM2, BCL-2 and CCND1.
However, the pathogenic significance for any of these genes has not been established.
Mutations in certain genes have been well described for cutaneous melanoma. Examples of
such genes are the oncogenes NRAS, BRAF and AKT3, and the tumour suppressors
CDKN2A, PTEN and TP53. In contrast to skin melanomas, PTEN mutations were not ob‐
served in a study of nine cell lines (Naus et al, 2000). Nevertheless, in 15% of the UM cases
mutations in PTEN were found resulting in activation of AKT and overexpression of the
PI3K-PTEN-AKT pathway preventing apoptosis (Abdel-Rahman et al, 2006; Ehlers et al,
2008; Ibrahim & Haluska, 2009).
7.3.1. The RAS-RAF-MEK-ERK pathway
In a large proportion of the UMs the RAS-RAF-MEK-ERK pathway or mitogen-activated
protein  kinase  (MAPK)  pathway  is  constitutionally  activated,  leading  to  excessive  cell
proliferation and suggesting the presence of  activating mutations upstream in the path‐
way (Weber et al, 2003; Zuidervaart et al, 2005). Mutation analysis on potential mutation
sites in the BRAF gene were performed, since a single substitution (p.V600E) in BRAF oc‐
curs frequently in benign and premalignant cutaneous nevi (Davies et al, 2002; Pollock et
al,  2003).  However,  NRAS  and BRAF  mutations  have  been  reported  in  a  few UMs but
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overall these mutations are rare (Cohen et al, 2003; Kilic et al, 2004; Mooy et al, 1991; Sal‐
danha et al, 2004).
7.3.2. GNAQ and GNA11 gene
With the recent discovery of activating GNAQ and GNA11 mutations new light has been
shed on the MAPK pathway. Van Raamsdonk and co-workers demonstrated an alterna‐
tive route to MAPK activation through G-protein signalling in melanocytic neoplasia in‐
cluding UMs. They reported a GNAQ  mutation in 83% of blue naevi and in 46% of UM
cases (Van Raamsdonk et  al,  2009).  Other studies confirmed these results,  GNAQ  muta‐
tions were found in half  of  the UM cases (Bauer et  al,  2009;  Onken et  al,  2008).  GNAQ
and its  paralog GNA11  encode the  heterotrimeric  guanine  nucleotide-binding protein  G
subunit alpha q and 11, respectively. Through mutations these subunits become activated
and abrogate their intrinsic GTPase activity, which is required to return them to an inac‐
tive state.  This oncogenic conversion is suggested to be the cause of constitutive MAPK
pathway  activation.  A  subsequent  study  reported  that  83%  of  UM  samples  harboured
Gα-protein  mutations  (GNAQ  or  GNA11  mutations)  affecting  specific  regions  on  either
exon  4  or  5  (codon  R183  or  Q209,  respectively)  in  a  mutually  exclusive  pattern  (Van
Raamsdonk  et  al,  2010).  There  is  no  relation  between  GNAQ  mutations  and  prognosis
(Bauer et al, 2009). Hence, the presence of Gα-protein mutations in tumours at all stages
of  malignant  progression  and  in  melanocytic  lesions  of  the  choroid,  suggests  that  they
are early events in UM (Onken et al, 2008; Van Raamsdonk et al, 2009).
7.3.3. BAP1 gene
Exome  genome  sequencing  led  to  the  discovery  of  the  BRCA1  associated  protein  1
(BAP1) gene in UM (Harbour et al, 2010). BAP1, a nuclearly localized enzyme, was origi‐
nally  identified  as  an  ubiquitin  hydrolase  that  binds  to  the  RING  finger  domain  of
BRCA1 (Farmer et al, 2005; Jensen et al, 1998). It has de-ubiquitinating activity and is in‐
volved in several biological processes, including regulation of cell cycle and cell growth,
chromatin dynamics and DNA damage response (Farmer et al, 2005). BAP1 is located on
chromosome 3p21.1 and is  thought to be a tumour suppressor gene (Ventii  et  al,  2008).
Mutations  in  this  gene  first  have  been  reported  in  a  small  number  of  breast  and  lung
cancer cell lines (Jensen et al, 1998). Recently, inactivating somatic mutations were found
in 84% of the metastasizing UMs. These mutations were only found in 1 out of 26 inves‐
tigated class 1 tumours against 26 out of 31 class 2 tumours, implicating that BAP1 muta‐
tions occur late in the UM progression (Harbour et al,  2010).  In addition, co-segregating
germline BAP1  mutations have been described in several families with different range of
diseases, such as cutaneous melanomas (Wiesner et al, 2011), malignant pleural mesothe‐
liomas (Testa  et  al,  2011),  and other  cancers  such as  meningioma (Abdel-Rahman et  al,
2011).  Given  the  functional  complexity  of  BAP1,  different  germline  mutations  in  BAP1
may  predispose  to  divergent  tumour  types.  To  understand  more  about  the  impact  of
BAP1 mutations on UM and other types of cancers, more extensive clinical, molecular ge‐
netic, and functional studies are ongoing.
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8. Metastases
Irrespective of primary treatment of the UM nearly half of the patients develop metastases
(Gilissen et al, 2011). UM spreads haematogenous, with a high tendency to metastasize to
the liver in 90-95% of the patients. One explanation for the development of new distant
metastasis years after the control of primary tumour is the presence of circulating tumour
cells at time of the initial diagnosis (Manschot et al, 1995). In other words, the disease is of‐
ten already disseminated at time of tumour diagnosis. Several pathways have been implicat‐
ed in the preferential homing of tumour cells to the liver, such as hepatocyte growth factor
(HGF) and it’s corresponding receptor c-Met, insulin-like growth factor 1 (IGF-1), and che‐
mokine CXCL12 (Bakalian et al, 2008). In case of liver metastasis prognosis is poor with a
median survival of approximately 8 months (Eskelin et al, 2003).
Despite the fact that there a no therapeutic options for metastatic UM that improve sur‐
vival or quality of life, the following methods can be used for screening of liver metasta‐
sis: liver function tests (gamma-glutamyl transpeptidase (γGT) and lactate dehydrogenase
(LDH) from blood), liver imaging with US, CT and MRI. Although screening annually or
semi-annually for liver metastasis by liver function tests are being widely used, there are
reports  of  disseminated  liver  metastases  and  normal  liver  function  tests  (Donoso  et  al,
1985; Eskelin et al, 1999).
Patients have 97.5% chance or more of having no metastasis in the case of normal liver func‐
tion tests, because of the high negative predictive value. However, isolated or combined liv‐
er function tests for aspartate aminotransferase (AST), alanine transaminase (ALT), yGT,
LDH and phosphatidic acid (PA) are not indicated for detection of early liver metastasis
(Mouriaux et al, 2012). Other upcoming screening options make use of serum markers,
Among which S-100β (neural crest marker), melanoma inhibitory activity (MIA), tissue pol‐
ypeptide specific antigen (TPS) and osteopontin (OPN). MIA and S-100β showed significant
increase in levels before clinical diagnosis of metastasis (Barak et al, 2011). In a lead time of
more than 6 months before clinical metastasis a significant increase in OPN and steeper
trendlines in MIA and S-100β levels were demonstrated (Hendler et al, 2011).
9. Treatment of primary UM
Conservation of the eye in UM with useful vision has improved with advances in local irra‐
diation (brachytherapy), heavy particle radiation techniques (proton and helium ion beam),
stereotactic radiotherapy (SRT), endoresection, exoresection, transpupillary thermotherapy
and photodynamic therapy (Spagnolo et al, 2012). If the tumours are larger, advanced and,
in particular, if there is evidence of extraocular extension enucleation is advised (Spagnolo
et al, 2012). In addition, enucleation is also performed after serious treatment induced com‐
plications (Hungerford, 1993; Shields et al, 1991). Choice of treatment depends on the loca‐
tion and size of the tumour and goals of therapy. Even though enucleation is sometimes
required, eye-preserving approaches have shown to be equally successful regarding overall
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survival and metastasis-free survival (Seddon et al, 1985; Seddon et al, 1990). Brachytherapy
is the most common method for treating UM, and currently the ruthenium-106 (Ru-106) and
iodine-125 (I-125) applicators are the most frequently used. Brachytherapy can be used in
combination with other methods of treatment of UM, such as local resection or transpupil‐
lary thermotherapy (Pe'er, 2012). Local control with plaque radiotherapy has provided over‐
all survival comparable to enucleation. Radiation-induced side effects have necessitated
secondary enucleation in 10-22% of the patients (Bell & Wilson, 2004; Char et al, 1993; Fin‐
ger, 1997; Garretson et al, 1987; Gunduz et al, 1999; Lommatzsch et al, 2000; Packer et al,
1992; Shields et al, 1991; Tjho-Heslinga et al, 1999; Vrabec et al, 1991). Local recurrences after
brachytherapy are reported between 4 - 28%, depending on the size of the tumour and the
follow up time (Damato & Foulds, 1996; Gragoudas, 1997; Karlsson et al, 1989; Seregard et
al, 1997; Tjho-Heslinga et al, 1999; Wilson & Hungerford, 1999; Zografos et al, 1992). Radia‐
tion-induced complications include radiation retinopathy, radiation maculopathy, radiation
opticopathy as well as recurrences (Gragoudas et al, 1999; Kinyoun et al, 1996; Summanen et
al, 1996). Heavy particle radiation with positive charged particles (protons or helium-ions)
enables treatment of small, medium- and large-choroidal melanomas. The local recurrence
rate for proton beam irradiation is similar to brachytherapy and at 10 years is usually
around 5% (Gragoudas, 1997; Zografos et al, 1992). Secondary enucleation is performed in
10 - 15% of patients either due to complications or local recurrence. Other complications,
such as maculopathy, opticopathy, cataract, glaucoma, vitreous haemorrhage, retinal de‐
tachment and dryness have also been described (Desjardins et al, 2012). In concordance with
proton beam irradiation radiogenic side effects are also reported after SRT. Side effects, such
as radiation retinopathy, opticopathy and neovascular glaucoma are responsible for the ma‐
jority of secondary visual loss and secondary enucleations after SRT (Mueller et al, 2000; Ze‐
hetmayer et al, 2000). The efficacy of SRT for UM has been proven in different studies with
local tumour control rates reported over 90%, 5 and 10 years after treatment (Zehetmayer,
2012). Local resection (endoresection and exoresection) of UM aims to conserve the eye and
remain a useful vision. The tumour can be removed in several manners, through the vitrous
and retinal with a vitreous cutter, endoresection, or through a scleral opening exoresection.
Variations of exoresection include iridectomy, iridocyclectomy, cyclochoroidectomy, and
choroidectomy. Endoresection as well as exoresection can be used as a primary procedure,
after another conservative therapy as a treatment option for recurrences or toxic tumour
syndrome. An advantage of local resection is that eyes that would otherwise be inoperable
can be preserved, while relative large tumour samples are available for prognostication and
research (Damato & Foulds, 1996; Damato, 2012; Robertson, 2001).
10. Treatment of liver metastases
Although treatment  options  for  small  to  medium sized melanoma improves  visual  out‐
come, there has not been any standardized therapy that improves survival in metastatic
disease. Systemic treatment options, such as intravenous chemotherapy and immunother‐
apy do not  seem to give promising results  or  survival  benefit  (Augsburger et  al,  2009).
Diagnosis, Histopathologic and Genetic Classification of Uveal Melanoma
http://dx.doi.org/10.5772/53631
155
Several  locoregional  techniques  are  available,  for  example  immunoembolization,  chemo‐
embolization,  isolated liver  perfusion and hepatic  intra-arterial  chemotherapy.  In  highly
selected patients, surgical resection of liver metastases can be beneficial. Operating on pa‐
tients  with  a  time  from  diagnosis  of  the  primary  tumour  to  liver  metastases  of  >  24
months,  ≤  4  liver  metastatic  lesions  and  absence  of  ‘miliary’  disease  (multiple,  diffuse,
millimetre-sized, dark punctuate lesions on CT) is associated with prolonged survival. A
median survival of  27 months has been described in patients with microscopically com‐
plete liver resection versus 14 months in patients with microscopically or macroscopically
incomplete liver resection (Mariani et al, 2009).
11. Future prospects
With the discovery of GNAQ and BAP1 mutations, new therapeutic strategies based on the
specific mutated gene content seem promising. For tumours with Gα-protein mutations, the
therapeutic goal is to inhibit downstream signalling molecules in the MAPK pathway that
are activated. Preclinical studies show that inhibition of MAPK pathway in UM cell lines re‐
sults in decreased cell proliferation (Van Raamsdonk et al, 2009). There are several key mol‐
ecules in the MAPK pathway, which have been explored as potential therapeutic targets.
One of such is MEK, and Gα-protein mutant UM cells showed to be mildly sensitive to the
MEK inhibitor AZD6244 (Gill & Char, 2012). Another recent preclinical study proposed to
target both the MAPK and PI3K/AKT pathway since both pathways are activated in UM. A
combination of MEK and PI3K inhibition treatment resulted in induction of apoptosis in a
Gα-mutant UM cells (Khalili et al, 2012). Other potential targets in the MAPK pathway are
currently being investigated, including protein kinase C, which is a component of signalling
from GNAQ to Erk1/2 (Wu et al, 2012).
Therapeutically targeting UMs with a BAP1 mutation works in a different manner than the
Gα-protein mutations, since BAP1 acts as a tumour suppressor gene. Regaining lost func‐
tions of suppressor genes are in general more challenging than inhibiting an overactive on‐
cogene. Nevertheless, ongoing studies show that histone deacetylase (HDAC) inhibitors
may have therapeutic potential in UM. Landreville and colleagues established that HDAC
inhibitors can reverse the histone H2A hyperubiquitination that occurs in cultured UM cells
depleted of BAP1, and it induces morphologic differentiation, cell-cycle exit, and shifts to a
differentiated, melanocytic GEP (Landreville et al, 2012). Examples of HDAC inhibitors are
valproic acid, trichostatin A, LBH-589, and suberoylanilide hydroxamic acid. Clinical trials
are needed to evaluate the effect of these compounds in UM patients, and hopefully UM
specific treatment based on mutational content will lead to improved patient survival.
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